Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nauclea officinalis extract syrup is a Traditional Chinese Medicine (TCM) preparation derived from the aqueous extract of the stems and branches of *Nauclea officinalis* (also known as Danmu). It is primarily indicated for the treatment of acute upper respiratory tract infections, acute tonsillitis, and acute pharyngitis, particularly in pediatric populations. The extract contains various bioactive compounds, including indole alkaloids (such as nauclefine and angustine) and quinovic acid glycosides, which contribute to its anti-inflammatory, analgesic, and antibacterial properties. In clinical practice, it is used to clear heat and detoxify and relieve swelling and pain. A Phase 4 post-marketing study (ChiCTR1800016745) was conducted by West China Second University Hospital to further evaluate its efficacy and safety in children compared to other standard TCM treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nauclea officinalis extract syrup.